This clinical trial is focused on studying a condition known as Acute Respiratory Distress Syndrome (ARDS), which can occur due to pneumonia or other infections. ARDS is a serious lung condition that makes it difficult to breathe. The study is testing a treatment called Recombinant Human Plasma Gelsolin, also known as rhu-pGSN, which is given through an intravenous infusion. This means the treatment is administered directly into the bloodstream through a vein. The trial will compare the effects of rhu-pGSN with a placebo, which is a substance with no active medication, to see if rhu-pGSN is safe and beneficial for patients with moderate-to-severe ARDS.

The purpose of the study is to evaluate how well rhu-pGSN works in combination with the standard care that patients with ARDS usually receive. Participants in the study will be randomly assigned to receive either rhu-pGSN or a placebo, along with their regular treatment. The study will monitor participants over a period of time to assess their recovery and any side effects they may experience. The main focus will be on the survival rate of participants and their need for respiratory support, such as ventilators, during the study period.

Throughout the study, researchers will collect information on how many days participants can breathe without the help of a ventilator and how long they stay in the hospital. The study will also look at the overall safety of rhu-pGSN by tracking any new or worsening health issues that occur. This research aims to provide valuable insights into whether rhu-pGSN can improve outcomes for patients suffering from ARDS due to infections like pneumonia.